ResMed (RMD) - Stock price history - CompaniesMarketCap.com
Jun 5, 1995 · Stock price history for ResMed from 1995 to 2025.
ResMed (NYSE:RMD) Downgraded to "Hold" Rating by Baird R W
1 day ago · Weiss Ratings reissued a "hold (c+)" rating on shares of ResMed in a report on Monday. KeyCorp upped their target price on ResMed from $298.00 to $299.00 and gave the stock an …
ResMed (RMD): Evaluating the Stock’s Valuation After FDA Clearance …
2 days ago · ResMed (RMD) just secured FDA clearance for its AI driven Smart Comfort feature, a personalized CPAP comfort system built on over 100 million nights of sleep data, and investors are …
Healthcare Stocks Analysis 2025: Sell Surgery Partners, Watch ResMed ...
1 day ago · A 2025 analysis of two healthcare stocks: Surgery Partners (SGRY) is flagged as a sell due to poor metrics, while ResMed (RMD) is highlighted for strong growth and cash flow margins.
ResMed - 30 Year Stock Price History | RMD | MacroTrends
Historical daily share price chart and data for ResMed since 1995 adjusted for splits and dividends.
RMD Stock Set to Gain From FDA Clearance of AI-Enabled ... - sharewise
Dec 9, 2025 · Resmed’s Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings to help people with OSA start and maintain CPAP …
ResMed share price is on watch for all-time highs
The ResMed share price is nearing record territory after strong FY 2025 results, upbeat guidance, and a $150m buyback plan.
How FDA-Cleared AI Smart Comfort Personalization At ResMed (RMD) …
5 days ago · In December 2025, ResMed announced it had received U.S. FDA clearance for Smart Comfort, an AI-enabled feature that uses more than 100 million nights of de-identified sleep data to …
Historical Data - Nasdaq
Historical data provides up to 10 years of daily historical stock prices and volumes for each stock. Historical price trends can indicate the future direction of a stock.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins …
Aug 1, 2025 · Resmed delivered an earnings and revenue beat in the fourth quarter of fiscal 2025. The performance reflected robust global demand for its sleep and breathing health devices, as well as an ...